口服4型与7型腺病毒活疫苗在美国疫苗不良事件报告系统(VAERS)中的不良事件分析(2011年10月-2018年7月)
该研究检索VAERS数据库2011年10月至2018年7月接种腺病毒疫苗后的美国报告,共纳入100份报告,其中39%为严重不良事件。最常见的严重不良事件为吉兰-巴雷综合征(GBS,n=12)和过敏反应(n=8),未发现非预期或令人担忧的不良事件模式。
要点
- VAERS共收到100份腺病毒疫苗接种后不良事件报告,39%为严重事件。
- 最常见严重不良事件为GBS(n=12)和过敏反应(n=8)。
- 严重不良事件报告率高于对照军营新兵人群(39% vs 18%)。
核心结论
- 腺病毒疫苗严重不良事件报告率高于对照军营新兵人群(39% vs 18%),但未发现非预期或令人担忧的不良事件模式。
- GBS和过敏反应可能与同时接种其他疫苗及肌注青霉素G等暴露有关。
研究设计与样本
- 研究检索VAERS数据库中2011年10月至2018年7月接种腺病毒疫苗后的美国报告,包括军事观察研究参与者。
- 共纳入100份报告,回顾所有严重报告及 accompanying 医疗记录,并与对照军营新兵人群比较严重报告比例。
主要发现
- 100份报告中39份(39%)为严重报告,其中17份(44%)来自观察研究。
- 报告1例死亡,男性占72%,接种者中位年龄19岁(范围17-32岁)。
- 最常见严重不良事件为GBS(n=12)和过敏反应(n=8);其中2例GBS和所有过敏反应报告来自观察研究。
- 95%的报告记录了同时接种多种其他疫苗,50%记录了同时使用肌注青霉素G或其他抗生素。
临床怎么用
- 接种腺病毒疫苗时应关注GBS和过敏反应等严重不良事件。
- 应评估同时接种其他疫苗及使用抗生素等暴露因素对不良事件的影响。
局限性
- VAERS为被动监测系统,存在报告偏倚和漏报,不能确定因果关系。
- 研究期间同时接种其他疫苗和抗生素的暴露常见,可能混杂不良事件观察。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In March 2011, the U.S. Food and Drug Administration licensed adenovirus type 4 and type 7 vaccine, live, oral (Barr Labs, Inc.) (adenovirus vaccine) for use in military personnel 17 through 50 years of age. The vaccine was first universally administered to U.S. military recruits in October 2011. We investigated adverse event (AE) reports following the adenovirus vaccine submitted to the Vaccine Adverse Event Reporting System (VAERS). METHODS: We searched the VAERS database for U.S. reports among persons who received adenovirus vaccine during October 2011 through July 2018 including participants in a military observational study. We reviewed all serious reports and accompanying medical records. We compared the proportion of serious reports in a proxy military recruit population and reviewed all reports of suspected allergic reactions following adenovirus vaccination. RESULTS: During the analytic period, VAERS received 100 reports following adenovirus vaccination; 39 (39%) were classified as serious and of these, 17 (44%) were from the observational study. One death was reported. Males accounted for 72% of reports. Median age of vaccinees was 19 years (range 17-32). The most frequently reported serious AEs were Guillain Barré syndrome (GBS) (n = 12) and anaphylaxis (n = 8); of these, two GBS and all the anaphylaxis reports were reported in the observational study. Reports documented concurrent receipt of multiple other vaccines (95%) and penicillin G (IM Pen G) or other antibiotics (50%). CONCLUSIONS: The reporting rate for serious AEs was higher than with other vaccines administered in the comparison military recruit population (39% vs 18%); however, we identified no unexpected or concerning pattern of adenovirus vaccine AEs. Co-administration of vaccines and IM Pen G was commonly reported in this military population. These exposures may have contributed to the GBS and anaphylaxis outcomes observed with the adenovirus vaccine. Future adenovirus vaccine safety studies in a population without these co-administrations would be helpful in clarifying the vaccine's safety profile.
引用
- McNeil MM, Paradowska-Stankiewicz I, Miller ER, et al. Adverse events following adenovirus type 4 and type 7 vaccine, live, oral in the Vaccine Adverse Event Reporting System (VAERS), United States, October 2011-July 2018. Vaccine. 2019. PMID: 31548014. doi:10.1016/j.vaccine.2019.08.087
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。